Lifecare Innovations Private Limited

lifecareinnovations.com

Lifecare Innovations is a R&D intensive company specialised in controlled release pharmaceuticals employing an array of technologies of novel drug delivery systems. The first product is a Liposome mediated delivery of Amphotericin B to target fungal or leishmania cells. Lifecare Innovations received Technology Day 2004 National Award for Bio-technology in recognition of the indigenous development and production of life saving drug - FUNGISOME. The award function was presided by His Excellency the President of India Dr. A.P.J. Abdul Kalam. The award and the citation were presented by the Minister of Science Technology and Ocean Development Mr. Kapil Sibbal. Lifecare Innovations is engaged in the development of number of other controlled release drugs in collaboration with national institutions. These are under various stages of development. Predominant among these are a range of anti-fungals. To complement anti-fungal treatment, Lifecare Innovations has also launched Itraconazole capsules under the brand name FUNGITRACE

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

news image

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More

BUSINESS INSIGHTS

IKTOS AND ZEALAND PHARMA TO DEVELOP ARTIFICIAL INTELLIGENCE TECHNOLOGY FOR PEPTIDE DRUG DESIGN

Iktos | June 22, 2022

news image

Iktos, a company specialized in Artificial Intelligence for new drug design, announced a research collaboration with Zealand Pharma A/S a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design. Iktos’ AI technology, based on a comprehensive data-driven chemical structure generation technology, brings new insights into the drug discovery process. This technology automatically...

Read More

SMALL MOLECULES LEAD IN RECENT NEW DRUG APPROVALS

DCAT Value Chain Insights | February 05, 2020

news image

Small molecules still lead over biologics in recent drug approvals, accounting for nearly three-fourths of drug approvals over the past several years, but will small molecules' dominance continue? DCAT Value Chain Insights takes an inside look. One measure to evaluate the role of small molecules versus biologics is to look how they have fared in recent approvals of new molecular entities (NMEs) by the US Food and Drug Administration’s Center for Drug Evaluation and Research. Between 20...

Read More

PHARMACY MARKET

THERMO FISHER SCIENTIFIC AND ASTRAZENECA TO CO-DEVELOP NGS-BASED COMPANION DIAGNOSTICS

Thermo Fisher Scientific | September 03, 2021

news image

Thermo Fisher Scientific's clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca's expanding portfolio of targeted therapies. The companies will collaborate under a multiyear, global agreement. "As the pipeline of targeted therapies expands, the availability of diagnostic tools that can interrogate multiple biomarkers simultaneously will ensure patient...

Read More
news image

PHARMA TECH

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More
news image

BUSINESS INSIGHTS

IKTOS AND ZEALAND PHARMA TO DEVELOP ARTIFICIAL INTELLIGENCE TECHNOLOGY FOR PEPTIDE DRUG DESIGN

Iktos | June 22, 2022

Iktos, a company specialized in Artificial Intelligence for new drug design, announced a research collaboration with Zealand Pharma A/S a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design. Iktos’ AI technology, based on a comprehensive data-driven chemical structure generation technology, brings new insights into the drug discovery process. This technology automatically...

Read More
news image

SMALL MOLECULES LEAD IN RECENT NEW DRUG APPROVALS

DCAT Value Chain Insights | February 05, 2020

Small molecules still lead over biologics in recent drug approvals, accounting for nearly three-fourths of drug approvals over the past several years, but will small molecules' dominance continue? DCAT Value Chain Insights takes an inside look. One measure to evaluate the role of small molecules versus biologics is to look how they have fared in recent approvals of new molecular entities (NMEs) by the US Food and Drug Administration’s Center for Drug Evaluation and Research. Between 20...

Read More
news image

PHARMACY MARKET

THERMO FISHER SCIENTIFIC AND ASTRAZENECA TO CO-DEVELOP NGS-BASED COMPANION DIAGNOSTICS

Thermo Fisher Scientific | September 03, 2021

Thermo Fisher Scientific's clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca's expanding portfolio of targeted therapies. The companies will collaborate under a multiyear, global agreement. "As the pipeline of targeted therapies expands, the availability of diagnostic tools that can interrogate multiple biomarkers simultaneously will ensure patient...

Read More